Atherosclerosis News and Research

RSS

Atherosclerosis is the progressive buildup of plaque - the fatty deposits and other cells - in the inner walls of the arteries. The condition is a consequence of elevated cholesterol and for many it's a silent disease, with no visible signs or symptoms. The disease can begin in early adulthood and continues to progress for the rest of a person's life. Despite the serious nature of atherosclerosis, many people do not understand how it develops and progresses.

Statin therapy should still be used first to reach blood cholesterol levels before considering niacin

Heart experts at Johns Hopkins are calling premature the early halt of a study by researchers at Walter Reed Army Medical Center and Washington Hospital Center on the benefits of combining extended-release niacin, a B vitamin, with cholesterol-lowering statin medications to prevent blood vessel narrowing. Cardiovascular atherosclerosis, as it is also known, is believed responsible for one in three deaths in the United States each year.

17 Nov 2009

Merck to market and develop cardiovascular medicines for a range of cardiovascular disorders

Following the completion of its merger with Schering-Plough, Merck today confirms and underscores its commitment to marketing and developing cardiovascular medicines for a range of cardiovascular disorders.

16 Nov 2009

Galapagos third quarter 2009 financial results in line with management expectations

Galapagos NV announces today that third quarter 2009 operational and financial results were in line with management expectations. These results encourage the Company to retain full year guidance of EUR 100 million revenues, a growth of 30% compared to 2008. Galapagos' service division BioFocus will significantly increase its cash contribution to the Group result for the full year 2009.

13 Nov 2009

BioInvent International, Daiichi Sankyo sign licence and discovery agreement

BioInvent International AB has announced that it has entered into a licence and discovery agreement with DAIICHI SANKYO COMPANY, LIMITED for the development of therapeutic antibodies against multiple targets. Under the terms of the collaboration, Daiichi Sankyo will be granted broad access to BioInvent's discovery and development technology platform and in house antibody expertise. As part of the agreement, BioInvent has secured certain co-promotion rights in Scandinavia and the Baltic countries.

13 Nov 2009

Results from first-in-man study of NO-donating HMG-CoA Reductase Inhibitor released

NicOx S.A. today announced that a phase 1b, first-in-man study for NCX 6560, versus placebo and Lipitor® (atorvastatin), has met its primary and secondary objectives. The top-line results demonstrated very good safety and tolerability for all the tested doses of NCX 6560, as well as the expected cholesterol lowering profile.

13 Nov 2009

Report on the epidemiology of PAD, TAO and CLI in India

A new analysis published by THE SAGE GROUP concludes that atherosclerotic peripheral arterial disease (PAD) afflicts over 20 million in India. Both PAD and CLI represent major and significantly underestimated problems for the Indian economy and healthcare system.

13 Nov 2009

New Cat B 750 FAST imaging agent launched by VisEn Medical

VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new Cat B 750 FAST(TM) imaging agent for measuring and monitoring cathepsin B activity associated with disease progression and therapeutic response in vivo. Cathepsin B expression is well known as a key biomarker and therapeutic target in a range of diseases, including atherosclerosis, oncology, and arthritis.

12 Nov 2009

Nuvo Research announces new licensing agreement for Oxoferin

Nuvo Research Inc., a Canadian drug development company focused on the research and development of drug products that are delivered to and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced a new licensing agreement for Oxoferin(TM), its topical wound healing agent, and additional details of the funding assistance to be provided by the Development Bank of Saxony for the development of WF10.

12 Nov 2009

Compugen discovers new biomarker for predisposition to type 2 diabetes using its GeneVa platform

Compugen Ltd. announced today the discovery and experimental confirmation of a genetic biomarker, CGEN-40001 for predisposition to type 2 diabetes, the most common form of diabetes.

9 Nov 2009

NIH grants $1 million to study whether Transcendental Meditation can prevent future heart attacks in CHD patients

The National Institutes of Health's National Heart, Lung, and Blood Institute will fund a $1 million collaborative study by the Center for Natural Medicine and Prevention at Maharishi University of Management Research Institute and Columbia University Medical Center to determine whether the stress-reducing Transcendental Meditation technique can help patients with coronary heart disease (CHD) prevent future heart attacks, strokes and death.

7 Nov 2009

Declining kidney function linked to higher risk of heart failure in individuals with or without kidney disease

Declining kidney function is linked to a higher risk of heart failure, heart attack, peripheral arterial disease, and early death in individuals with or without kidney disease, according to a pair of studies appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN).

6 Nov 2009

Higher levels of phosphorus in blood linked to increased calcification of coronary arteries, says study

Higher levels of phosphorus in the blood are linked to increased calcification of the coronary arteries— a key marker of heart disease risk, according to a study in an upcoming issue of Clinical Journal of the American Society of Nephrology (CJASN). "This may help to explain why even early-stage chronic kidney disease (CKD) is associated with increased cardiovascular risk that is not otherwise explained by traditional risk factors," comments Katherine R. Tuttle, MD (Providence Medical Research Center, Spokane, WA).

6 Nov 2009

Financial results for the second-quarter reported by Micrus Endovascular

Micrus Endovascular Corporation (Nasdaq: MEND) today reported financial results for the three and six months ended September 30, 2009 and increased fiscal 2010 revenue guidance.

5 Nov 2009

Study: Charcoal lessens atherosclerotic lesions in mice with kidney damage

Charcoal may provide a new approach to managing the high rate of heart disease in patients with advanced kidney disease, according to preliminary research being presented at the American Society of Nephrology's 42nd Annual Meeting and Scientific Exposition in San Diego, CA.

2 Nov 2009

VIA Pharmaceuticals to discuss its cardio-metabolic product portfolio at the Target 2009 conference

VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic diseases, today announced that Dr. Rebecca Taub, Senior Vice President Research & Development will present "Liver Directed Beta Agonist for Targeting Cardiometabolic Disease", and will discuss the Company's cardio-metabolic product portfolio, including VIA's inhibitor of 5 Lipoxygenase, its THR Beta Agonist, and its DGAT1 development programs, at the Cambridge Healthtech Institute Seventh International Discovery on Target 2009 program, on November 3, 2009 in Boston, MA.

30 Oct 2009

Winners of 4th annual Katz Prizes in Cardiovascular Research announced

Columbia University Medical Center today announces the winners of the 4th annual Katz Prizes in Cardiovascular Research, with the senior scientist prize being awarded to an internationally renowned researcher from the National Institutes of Health, and the young investigator prize recognizing a cardiovascular researcher actively studying left ventricular assist devices and heart function.

30 Oct 2009

CCS updates the Canadian guidelines for the management and treatment of dyslipidemia

The management of dyslipidemia continues to evolve and despite improvements in recurrent cardiovascular events and a decrease in cardiac mortality, cardiovascular disease (CVD) still represents the major burden of disease in this country.

29 Oct 2009

Treatment of angina patients with ivabradine reduces risk of cardiovascular death

Dramatic reductions in hospitalization for heart attacks and in the need for revascularization surgery were achieved in angina patients treated with the selective heart rate reduction medication ivabradine on top of current standard treatment, according to results of a major clinical study presented today at the 2009 Canadian Cardiovascular Congress in Edmonton.

29 Oct 2009

NeuroVasx cPAX Aneurysm Treatment System: first procedure in Spain performed

NeuroVasx, Inc., a medical device company that develops technologies for the treatment of hemorrhagic and ischemic stroke, announced today that the first procedure in Spain utilizing its cPAX Aneurysm Treatment System was performed in Madrid. cPAX received CE Mark earlier this year.

28 Oct 2009

New CCS guidelines and position papers for physicians and nurse practitioners

Several new guidelines and position papers offering the most up to date information to ensure that clinicians practice evidence-based medicine were released at the Canadian Cardiovascular Congress 2009 this week.

28 Oct 2009

Atherosclerosis News and Research

Further Reading

Statin therapy should still be used first to reach blood cholesterol levels before considering niacin

Merck to market and develop cardiovascular medicines for a range of cardiovascular disorders

Galapagos third quarter 2009 financial results in line with management expectations

BioInvent International, Daiichi Sankyo sign licence and discovery agreement

Results from first-in-man study of NO-donating HMG-CoA Reductase Inhibitor released

Report on the epidemiology of PAD, TAO and CLI in India

New Cat B 750 FAST imaging agent launched by VisEn Medical

Nuvo Research announces new licensing agreement for Oxoferin

Compugen discovers new biomarker for predisposition to type 2 diabetes using its GeneVa platform

NIH grants $1 million to study whether Transcendental Meditation can prevent future heart attacks in CHD patients

Declining kidney function linked to higher risk of heart failure in individuals with or without kidney disease

Higher levels of phosphorus in blood linked to increased calcification of coronary arteries, says study

Financial results for the second-quarter reported by Micrus Endovascular

Study: Charcoal lessens atherosclerotic lesions in mice with kidney damage

VIA Pharmaceuticals to discuss its cardio-metabolic product portfolio at the Target 2009 conference

Winners of 4th annual Katz Prizes in Cardiovascular Research announced

CCS updates the Canadian guidelines for the management and treatment of dyslipidemia

Treatment of angina patients with ivabradine reduces risk of cardiovascular death

NeuroVasx cPAX Aneurysm Treatment System: first procedure in Spain performed

New CCS guidelines and position papers for physicians and nurse practitioners

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News